Biocardia Inc SEC Filings

BioCardia, Inc.'s president, CEO and director reported open-market purchases of the company’s common stock. On December 16, 2025, the reporting person bought 200 shares of BioCardia common stock at a weighted average price of $1.37 per share, executed in multiple trades between $1.28 and $1.46 per share. On December 17, 2025, they bought an additional 900 shares at a weighted average price of $1.30 per share, with individual trade prices ranging from $1.23 to $1.38 per share. After these transactions, the reporting person beneficially owned 267,966 shares of BioCardia common stock, held directly.

BioCardia, Inc. reported that Japan’s Pharmaceutical and Medical Device Agency has agreed to let the company move its CardiAMP Cell Therapy for the treatment of heart failure with reduced ejection fraction into a formal clinical consultation process. This follows completion of a third preliminary clinical consultation with the agency. If, in that formal consultation, the PMDA concludes that the available data provide sufficient evidence of safety and efficacy, BioCardia would be able to file for regulatory approval in Japan for this cell therapy.

BioCardia, Inc. Senior Vice President, Devices reported equity compensation activity. On December 8, 2025, the executive acquired 38,078 restricted stock units (RSUs), each equal to one share of common stock awarded as compensation in lieu of cash, with 100% of the RSUs vesting on that date. To cover income tax withholding for the vested RSUs, 15,172 shares were withheld by BioCardia, which is not a sale by the executive. After these transactions, the executive beneficially owned 31,874 shares of common stock. The filing also reports a grant of a stock option for 20,000 shares at an exercise price of $1.37 per share, expiring on December 8, 2035, vesting as to 1/48th of the shares starting January 8, 2026 and monthly thereafter, contingent on continued service.

BioCardia, Inc. director reports new stock option grant

A BioCardia, Inc. director filed a Form 4 reporting the grant of a stock option on 12/08/2025. The option gives the right to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. According to the filing, all of these shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date.

After this grant, the reporting person beneficially owns 15,313 derivative securities, held directly. The option is shown with an expiration date of 12/08/2035, providing a long-term window during which the director may choose to exercise the option once vested.

BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.

BioCardia, Inc. director receives new stock option grant. A company director reported receiving a stock option to buy 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share, granted on 12/08/2025.

According to the filing, all of the shares under this option vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date. After this grant, the reporting person beneficially owns 15,573 derivative securities (stock options) on a direct basis, with the reported option expiring on 12/08/2035.

BioCardia, Inc. reported an insider equity award for one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option is classified as a derivative security because it represents the right to buy common stock in the future at a fixed price.

All 12,000 option shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues to serve as a service provider through that date. The option expires on 12/08/2035 if not exercised earlier. After this grant, the director beneficially owns 12,000 derivative securities directly in the form of this stock option.

BioCardia, Inc. filed an initial ownership report showing no securities held by the reporting director. A Form 3 was filed for an individual who serves as a director of BioCardia, Inc. (ticker BCDA) for an event dated 12/02/2025. The filing indicates that the form is filed by one reporting person and includes a remark stating that no securities are beneficially owned. An Exhibit 24 power of attorney is referenced, authorizing the signatory to sign on behalf of the reporting person.

BioCardia, Inc. (BCDA) reported an organizational update. The company announced in an 8-K that, on November 24, 2025, it issued a press release appointing Farhan Shahab as Vice President of Quality. This role typically oversees and supports quality systems and compliance for products and operations, which is important for companies operating in regulated medical and life science markets.

The press release describing the appointment is included as Exhibit 99.1, and the company notes that this information is being furnished, not filed, under securities laws, meaning it is provided for disclosure purposes without triggering certain liability provisions.